BMS-279700

BMS-279700 is an orally active Src-family kinase p56Lck inhibitor. BMS-279700 can block the production of proinflammatory cytokines (IL-2 and TNFα) . BMS-279700 can inhibit T cell proliferation. BMS-279700 can be used for the researches of inflammation and immunology[1].

Product Specifications

CAS Number

[240814-54-4]

UNSPSC

12352005

Target

Interleukin Related; Src; TNF Receptor

Related Pathways

Apoptosis; Immunology/Inflammation; Protein Tyrosine Kinase/RTK

Field of Research

Inflammation/Immunology

Smiles

C[C@H](NCC1)CN1C2=CC=C3C(N4C(C(NC5=C(C=CC=C5Cl)C)=N3)=CN=C4)=N2

Molecular Formula

C21H22ClN7

Molecular Weight

407.90

References & Citations

[1]Chen P, et al. Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S) -N- (2-chloro-6-methylphenyl) -2- (3-methyl-1-piperazinyl) imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity. J Med Chem. 2004 Aug 26;47 (18) :4517-29.